BRONCUS-B：(I)ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025;AND(II)PROPOSEDAMENDMENTSTOTHEEXISTINGMEMORANDUMANDARTICLESOFASSOCIATIONANDADOPTIONOFTHENEWMEMORANDUMANDARTICLESOFASSOCIATION.pdf

《BRONCUS-B：(I)ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025;AND(II)PROPOSEDAMENDMENTSTOTHEEXISTINGMEMORANDUMANDARTICLESOFASSOCIATIONANDADOPTIONOFTHENEWMEMORANDUMANDARTICLESOFASSOCIATION.pdf》由会员分享，可在线阅读，更多相关《BRONCUS-B：(I)ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025;AND(II)PROPOSEDAMENDMENTSTOTHEEXISTINGMEMORANDUMANDARTICLESOFASSOCIATIONANDADOPTIONOFTHENEWMEMORANDUMANDARTICLESOFASSOCIATION.pdf（44页珍藏版）》请在三个皮匠报告上搜索。

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Broncus Holding Corporation堃博醫療控股有限公司(Incorporated in the Cayman Islands with limited liability)(Stock Code:2216)(I)ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31,2025;AND(II)PROPOSED AMENDMENTS TOTHE EXISTING MEMORAND

3、UM ANDARTICLES OF ASSOCIATION ANDADOPTION OF THE NEW MEMORANDUMAND ARTICLES OF ASSOCIATIONThe Board is pleased to announce the audited consolidated results of the Company and its subsidiaries for the Reporting Period,together with the audited comparative figures for the year ended December 31,2024.F

4、INANCIAL HIGHLIGHTSYear ended December 31,Year ended December 31,2025USD0002024USD000Year-to-yearchangeRevenue1748,131-97.9%Sale of medical devices and consumables and provision of services6,0678,131-25.4%One-off sales return(5,893)Gross(loss)/profit(917)6,139-114.9%Loss for the year(17,875)(15,303)

5、16.8%Add:Share awards962236389.4%Non-IFRS adjusted net loss for the year(1)(16,913)(15,067)12.3%Cash and bank balances and deposits124,921139,346-10.4%(1)Please refer to the section headed“Non-IFRS Measures”in this announcement for more details.2BUSINESS HIGHLIGHTS Lung Cancer Interventional Therapy

6、 Products Approved for Launch in China,with Steady Advancements in CommercializationDuring the Reporting Period,our proprietary core product,the BroncAblate Transbronchial Radiofrequency Ablation System(“BroncAblate”)was approved for marketing in the PRC by the National Medical Products Administrati